Mandate

Vinge advises Aspiro in capital raising

June 16, 2014

Aspiro AB (publ) has published a rights issue prospectus for approximately SEK 65.8 million before transactions costs. The rights issue is fully subscribed by, among others, the principal owner, Streaming Media AS, a company within the Schibsted group. The rights issue is intended to strengthen the company’s financial position and implement the company’s strategies.

Vinge advised Aspiro in connection with the rights issue. Vinge’s team primarily consisted of Jesper Schönbeck, Oskar Bellani and Amanda Granqvist.

Aspiro is a media technology company which is playing a prominent role in redefining music consumption. The company offers WiMP, a premium music streaming service for consumers with HiFi quality audio and the first and only multimedia service with integrated editorial, magazine and video content. In addition, Aspiro is also a content supplier to the media industry through the syndicated platform, RADR, and helps its partners to attract and retain visitors on their websites. For more information, visit www.aspiro.com.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025